A Phase I study of BCL2 inhibitor VEN and MDM2 inhibitor idasanutlin in R/R AML was discontinued because of the poor efficacy, the safety was well tolerated, suggesting that the combination of targeted agents was feasible for R/R AML [93]. Here, BCL2 is linked to acute myeloid leukemia.